GlassScriptPhysician profile
Dan V Freeland
NPI 1336258847
$2,096.76
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $827 · 2020: $585 · 2021: $369 · 2022: $119 · 2023: $197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $196.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.94 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $254.36 | 2019-2022 | |
| Lilly USA, LLC | $186.90 | 2019-2023 | Mounjaro |
| Allergan, INC. | $150.68 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.08 | 2019-2021 | |
| Abbvie INC. | $104.45 | 2021-2023 | |
| Pfizer INC. | $93.78 | 2019-2020 | |
| Glaxosmithkline, LLC. | $92.57 | 2019-2023 | Shingrix, Trelegy Ellipta |
| Genentech USA, INC. | $78.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.04 | 2019-2021 | |
| Amarin Pharma, INC. | $46.47 | 2020-2021 | |
| Antares Pharma, INC. | $43.18 | 2022-2023 | Nocdurna, Tlando, Xyosted |
| Bausch Health US, LLC | $40.01 | 2023 | Aplenzin, Wellbutrin |
| Exact Sciences Corporation | $20.75 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $20.23 | 2019 | |
| Mayne Pharma Commercial LLC | $19.35 | 2023 | |
| Avanir Pharmaceuticals, INC. | $18.19 | 2019 | |
| Amgen INC. | $17.91 | 2022 | |
| Sanofi Pasteur INC. | $16.58 | 2020 | |
| Acella Pharmaceuticals, LLC | $13.38 | 2023 | NP Thyroid 60 |
| Shire North American Group INC | $13.00 | 2019 | |
| Abbott Laboratories | $12.43 | 2019 | |
| Merck Sharp & Dohme LLC | $11.09 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Freeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.